Brokerages expect Biomerica, Inc. (NASDAQ:BMRA) to report ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Biomerica’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.08). Biomerica also posted earnings per share of ($0.08) in the same quarter last year. The company is expected to issue its next earnings report on Thursday, August 29th.
On average, analysts expect that Biomerica will report full year earnings of ($0.24) per share for the current fiscal year, with EPS estimates ranging from ($0.24) to ($0.23). For the next fiscal year, analysts forecast that the business will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.38) to ($0.27). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Biomerica.
Biomerica (NASDAQ:BMRA) last released its earnings results on Monday, April 15th. The company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). Biomerica had a negative return on equity of 54.33% and a negative net margin of 44.07%. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.58 million.
A hedge fund recently bought a new stake in Biomerica stock. Perritt Capital Management Inc. bought a new position in Biomerica, Inc. (NASDAQ:BMRA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 40,000 shares of the company’s stock, valued at approximately $68,000. Perritt Capital Management Inc. owned 0.43% of Biomerica as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.31% of the company’s stock.
Shares of BMRA stock traded up $0.02 during mid-day trading on Friday, hitting $2.35. The stock had a trading volume of 4,777 shares, compared to its average volume of 35,524. Biomerica has a fifty-two week low of $1.60 and a fifty-two week high of $4.20. The stock has a market capitalization of $22.52 million, a PE ratio of -13.79 and a beta of 1.27.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Featured Article: The components of the Stochastic Momentum Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.